Marco Rossi

7.2k total citations
144 papers, 4.7k citations indexed

About

Marco Rossi is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Marco Rossi has authored 144 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 38 papers in Hematology and 29 papers in Genetics. Recurrent topics in Marco Rossi's work include Multiple Myeloma Research and Treatments (26 papers), Glioma Diagnosis and Treatment (22 papers) and MicroRNA in disease regulation (11 papers). Marco Rossi is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Glioma Diagnosis and Treatment (22 papers) and MicroRNA in disease regulation (11 papers). Marco Rossi collaborates with scholars based in Italy, United Kingdom and United States. Marco Rossi's co-authors include Pierfrancesco Tassone, James W. Young, Nicola Amodio, Maria Teresa Di Martino, John T. Hughes, Pierosandro Tagliaferri, Margaret M. Esiri, Hugh B. Coakham, Cirino Botta and Antonino Neri and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Marco Rossi

134 papers receiving 4.7k citations

Peers

Marco Rossi
David H. Lovett United States
Thomas Pap Germany
Claudia Wickenhauser Germany
Shai Izraeli Israel
Andrew Filer United Kingdom
Neil V. Morgan United Kingdom
Sandip M. Kanse Germany
Anna M. Randi United Kingdom
H. William Schnaper United States
Yasushi Adachi Japan
David H. Lovett United States
Marco Rossi
Citations per year, relative to Marco Rossi Marco Rossi (= 1×) peers David H. Lovett

Countries citing papers authored by Marco Rossi

Since Specialization
Citations

This map shows the geographic impact of Marco Rossi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Rossi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Rossi more than expected).

Fields of papers citing papers by Marco Rossi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Rossi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Rossi. The network helps show where Marco Rossi may publish in the future.

Co-authorship network of co-authors of Marco Rossi

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Rossi. A scholar is included among the top collaborators of Marco Rossi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Rossi. Marco Rossi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Alati, Caterina, Gaetana Porto, Mark Greve, et al.. (2025). SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. Cancers. 17(21). 3471–3471.
3.
Alati, Caterina, Matteo Molica, Gaetana Porto, et al.. (2025). CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues. Cancers. 17(18). 3027–3027. 2 indexed citations
4.
Molica, Matteo, Salvatore Perrone, Marco Rossi, & Diana Giannarelli. (2024). The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis. Leukemia Research. 144. 107549–107549. 1 indexed citations
5.
Molica, Matteo, Salvatore Perrone, & Marco Rossi. (2023). Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients. Journal of Clinical Medicine. 12(11). 3647–3647. 16 indexed citations
6.
Molica, Matteo, et al.. (2023). Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. Cancers. 15(20). 5060–5060. 2 indexed citations
7.
Markovic, Uroš, Alessandra Romano, Vittorio Del Fabro, et al.. (2021). Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in Oncology. 11. 624405–624405. 7 indexed citations
8.
Raimondi, Lavinia, Angela De Luca, Gianluca Giavaresi, et al.. (2020). Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. Non-Coding RNA. 6(3). 37–37. 12 indexed citations
9.
Morelli, Eugenio, Annamaria Gullà, Roberta Rocca, et al.. (2020). The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers. 12(2). 320–320. 25 indexed citations
10.
Tirinato, Luca, Francesca Scionti, Maria Laura Coluccio, et al.. (2020). Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling. ACS Omega. 5(47). 30436–30443. 29 indexed citations
11.
12.
Martino, Massimo, Mercedes Gori, Giovanni Tripepi, et al.. (2019). A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. Annals of Hematology. 99(2). 331–341. 4 indexed citations
13.
Amodio, Nicola, Maria Eugenia Gallo Cantafio, Cirino Botta, et al.. (2019). Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers. 11(2). 236–236. 35 indexed citations
14.
Martino, Massimo, Marco Rossi, Anna Ferreri, et al.. (2019). Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Review of Hematology. 12(8). 665–684. 16 indexed citations
15.
Rossi, Marco, Emanuela Altomare, Nicola Amodio, et al.. (2017). Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease. Blood. 130. 4380–4380. 2 indexed citations
16.
Leone, Emanuela, Eugenio Morelli, Maria Teresa Di Martino, et al.. (2013). Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth. Clinical Cancer Research. 19(8). 2096–2106. 184 indexed citations
17.
18.
Rossi, Marco & James W. Young. (2005). Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity. The Journal of Immunology. 175(3). 1373–1381. 253 indexed citations
19.
Ansari, Tahera, Paul Sibbons, A Parsons, & Marco Rossi. (2002). Quantitative neuropathological analysis of Sudden Infant Death Syndrome. Child Care Health and Development. 28(s1). 3–6. 6 indexed citations
20.
Rossi, Marco, et al.. (1999). CYSTIC LYMPHOCYTIC HYPOPHYSITIS, VISUAL FIELD DEFECTS AND HYPOPITUITARISM. International Journal of Clinical Practice. 53(8). 643–644. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David H. Lovett Breakdown of academic impact, for papers by Thomas Pap Breakdown of academic impact, for papers by Claudia Wickenhauser Breakdown of academic impact, for papers by Shai Izraeli Breakdown of academic impact, for papers by Andrew Filer Breakdown of academic impact, for papers by Neil V. Morgan Breakdown of academic impact, for papers by Sandip M. Kanse Breakdown of academic impact, for papers by Anna M. Randi Breakdown of academic impact, for papers by H. William Schnaper Breakdown of academic impact, for papers by Yasushi Adachi
Rankless by CCL
2026